The distribution of pathogenic and toxigenic genes among MRSA and MSSA clinical isolates

Fooladi, Abbas Ali Imani; Ashrafi, Elnaz; Tazandareh, Shafie Gorbani; Koosha, Roohollah Zarei; Sedighian, Hamid; Amin, Mohsen; Soori, Mina; Larki, Reza Abbasi; Choopani, Ali; Hosseini, Hamideh Mahmoodzadeh

doi:10.1016/j.micpath.2015.03.013

Cited by 39 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a new mecA homologue mecALGA251 shared 70% nucleotide homology with mecA [41], which results in possible false negative results by using this method. Meanwhile, the detection of the mecA gene is not specific to MRSA, because a small proportion of methicillin-susceptible Staphylococcus aureus (MSSA) with mecA gene and a large proportion of MRSA strains lack of mecA [42,43]. Combination CRISPR-Cas9 with optical DNA mapping was also applied to identify bacterial antibiotic resistance genes [39].…”

Section: Type Ii: Crispr-cas9 Based Diagnosticsmentioning

confidence: 99%

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia

Xiang

Qian

Zhang

et al. 2020

Journal of Drug Targeting

View full text Add to dashboard Cite

Emerging infectious diseases, the persistent potential for destabilising pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarise current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis. ARTICLE HISTORY

show abstract

Section: Type Ii: Crispr-cas9 Based Diagnosticsmentioning

confidence: 99%

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia

Xiang

Qian

Zhang

et al. 2020

Journal of Drug Targeting

View full text Add to dashboard Cite

show abstract

“…On the other hand, some researchers have already found a new mecA homologue ( mecALGA251 ) sharing only 70% nucleotide homology with mecA, which may cause false negative results in the test because of specificity of the method. Meanwhile, a large proportion of MRSA strains do not possess mecA , and there is a spot of MSSA strains that contains the mecA gene; this state of affairs make the detection of the mecA gene not specific to MRSA.…”

Section: Detection Of Pathogensmentioning

confidence: 99%

The applications of CRISPR/Cas system in molecular detection

Zhou

Peng

Zhang

2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

The Streptococcus pyogenes CRISPR/Cas system has found widespread applications as a gene‐editing and regulatory tool for the simultaneous delivery of the Cas9 protein and guide RNAs into the cell, thus making the recognition of specific DNA sequences possible. The recent study that shows that Cas9 can also bind to and cleave RNA in an RNA‐programmable manner is suggestive of potential utility of this system as a universal nucleic‐acid recognition tool. To increase the signal intensity of the CRISPR/Cas system, a signal amplification technique has to be exploited appropriately; this requirement is also a challenge for the detection of DNA or RNA. Furthermore, the CRISPR/Cas system may be used to detect point mutations or single‐nucleotide variants because of the specificity of the recognition between the target sequence and the CRISPR/Cas system. These lines of evidence make this technique capable of detecting pathogens during infection via analysis of their DNA or RNA. Thus, here we summarize applications of the CRISPR/Cas system to the recognition and detection of DNA and RNA molecules as well as the signal amplification. We also describe its potential ability to detect mutations and single‐nucleotide variants. Finally, we sum up its applications to testing for pathogens and potential barriers for its implementation.

show abstract

“…World Health Organization (WHO) stated that antimicrobial resistance us one of the most vital public health problem. 1 Data has shown that the yearly mortality rate caused by antimicrobial resistance infections are 23.000 in America, 25.000 in the Europe Union, and 58.000 in India. 2 These findings have stimulated a lot of global surveillance action.…”

Section: Antimicrobial Resistancementioning

confidence: 99%

“…16 For instance, SCCmec III is the most dominant types in countries like Arab, Indonesia, Thailand, Vietnam, China, Singapore, and India, which is also a type that showed resistance against cefoxitin, cephazolin, gentamycin, erythromycin, tetracycline, clindamycin, and cotrimoxazole. 23 Since 1996, the occurrence of infections caused by MRSA has increased, and accompanied with decreasing sensitivity for vancomycin (vancomycin-intermediate S. aureus) in the Europe, Asia, and America. Furthermore, in 2002, there was also reports about vancomycinresistant S. aureus/VISA.…”

mentioning

confidence: 99%

Potency of Xanthone Derivatives as antibacterial agent against Methicillin-Resistant Staphylococcus Aureus (MRSA)

Miladiyah

Rachmawaty

2017

JKKI

View full text Add to dashboard Cite

The distribution of pathogenic and toxigenic genes among MRSA and MSSA clinical isolates

Cited by 39 publications

References 34 publications

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia

The applications of CRISPR/Cas system in molecular detection

Potency of Xanthone Derivatives as antibacterial agent against Methicillin-Resistant Staphylococcus Aureus (MRSA)

Contact Info

Product

Resources

About